CClinicalTrials.gg
CompletedNCT03373448Updated Oct 24, 2022

Treatment of Mild to Moderate Peri-implantitis Using an Oscillating Chitosan Device

An interventional study of Labrida BioClean and Titanium curettes in Peri-Implantitis, sponsored by Labrida AS. Completed at 5 sites in 2 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by Labrida AS · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

34 patients diagnosed with mild to moderate peri-implantitis, defined as 2-4 mm peri-implant bone loss, will be randomized to either test treatment with Labrida BioClean® or control treatment with titanium curettes. In total 40 subjects (20 % drop-out rate), treated by 5 clinicians at 5 centers will be included in the study.

Read the detailed description

4.1 Study design The study will be a prospective multicentre randomized, examiner blinded controlled clinical trial of 24 months duration. Change in mucosal inflammation will be reported after 6 months while the true endpoint parameters i.e., peri-implant attachment will be reported after 1 and 2 years.

4.2 Treatment allocation and blinding Patients will be allocated either to test (Labrida BioClean® or control (titanium curettes) treatment by computer-generated block randomization to ensure equal sample sizes. The examiners will be blinded to the treatment allocation.

4.3 Study setting In total six centres will be included. Patient screening, inclusions and all clinical examinations will be performed by a board-certified specialist in periodontology, registered dental hygienist or specialist in prosthetics at each centre. Treatments will be performed by a dental hygienist or a board-certified specialist in periodontology.

4.4 Patients 40 patients (20+20) diagnosed with mild to moderate peri-implantitis, defined as peri-implant bone loss 2 -4 mm, will be included in the study.

4.5 Recruitment of patients

Patients referred to or seeking care in the included clinics will be screened for inclusion.

02

Conditions studied

  • Peri-Implantitis

Browse trials for

03

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Peri-implantitis defined as 2-4 mm bone loss distally, mesially or both, Probing Pocket Depth (PPD) ≥4mm and inflammation as demonstrated by Bleeding on Probing (mBoP) at least score 2.

In addition to the above mentioned main inclusion criteria, patients can be included if they meet the following conditions:

  1. Peri-implantitis as defined above on an implant that has been in function for more than 12 months prior to study start.
  2. Above 18 years of age.
  3. Eligible for treatment in an outpatient dental clinic (ie, ASA I and II).
  4. Had full-mouth plaque scores ≤20% prior to final inclusion and no visual plaque at the included implants prior to study start.
  5. Had at least one implant with a loading time of ≥ 12 months prior to baseline.
  6. Signed Informed Consent obtained prior to start.
  7. Psychological appropriateness.
  8. Consent to complete all follow-up visits.

Exclusion criteria

Exclusion Criteria:

Peri-implant bone loss > 4 mm, radiotherapy, chemotherapy, systemic long-term corticosteroid treatment, pregnancy or nursing, anatomical abnormalities, prosthetic factors making access to clinical measurements impossible.

In addition to the above mentioned main exclusion criteria, patients should be excluded if they meet any of the following conditions:

  1. Cemented supraconstructions and/or screw retained supraconstructions that for technical reasons makes it impossible to access implant for clinical measurements.
  2. Technical complications which according to the examiners judgement has contributed to the disease state and not possible to resolve prior to final inclusion.
  3. Mobile implant.
  4. Patients diagnosed with periodontal disease must have undergone causative treatment and be re-evaluated.
  5. Implants previously treated for peri-implantitis with grafting materials.
  6. Receiving medications known to induce mucosal hyperplasia.
  7. Uncontrolled diabetes HbA1c > 52, equals 7.0.
  8. Receiving systemic antibiotics \< 3 months prior to inclusion.
  9. Pregnant or lactating.
  10. Any condition or current treatment for any condition, which in the opinion of the investigator and/or consulting physician, may constitute an unwarranted risk.
  11. Presence of psychological characteristics, such as inappropriate attitude or motivation, which will influence treatment execution and treatment outcome.
  12. Unwillingness to undergo treatment.
  13. Advanced, untreated and uncontrolled peri-implantitis on neighbouring implants.
  14. If, in the opinion of the therapist, conditions are such that dental implants are deemed failing.
  15. Ongoing or previous radiotherapy to the head-neck region.
  16. Ongoing or previous chemotherapy.
  17. Systemic long-term corticosteroid treatment.
  18. Patients medicating with warfarine products or similar.

    -

04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Active comparator
    Labrida BioClean

    Labrida BioClean- chitosan device.The brush bristles of the test device (Labrida BioClean® LABRIDA AS, Oslo Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed thus not causing harm to the tissues surrounding the implant. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.

    Device: Labrida BioClean

  • Other
    Titanium curettes

    Peri-implant pockets will be debrided with titanium curettes.

    Other: Titanium curettes

Interventions

  • DeviceLabrida BioClean

    The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.

  • OtherTitanium curettes

    Peri-implant pockets will be debrided using titanium curettes.

05

What researchers measure

Primary outcomes

  1. Inflammation

    Reduction in peri-implant mucositis as measured clinically up to three months after therapy.

    Time frame: 3 months after first treatment

  2. Progression of bone loss

    True end-point

    Time frame: 12 months after first treatment.

Secondary outcomes

  1. Morbidity

    To compare patient morbidity after use of Labrida BioClean® versus titanium curettes determined on a VAS scale assessed at the 3 month treatment visit.

    Time frame: 3 months

  2. Adverse events

    To assess safety of BioClean™ by evaluating the occurrence of adverse events.

    Time frame: 12 months

06

Study locations

5 sites
  • Spesdent
    Oslo, 0352, Norway
  • Colosseum Majorstuen
    Oslo, 0369, Norway
  • Bjerke Tannmedisin AS
    Oslo, 0589, Norway
  • Odontologiska Institutionen
    Jönköping, 55111, Sweden
  • Blekingesjukhuset
    Karlskrona, 37185, Sweden
07

References and documents

Publications

  • Zeza B, Wohlfahrt C, Pilloni A. Chitosan brush for professional removal of plaque in mild peri-implantitis. Minerva Stomatol. 2017 Aug;66(4):163-168. doi: 10.23736/S0026-4970.17.04040-7. Epub 2017 May 10. PubMed 28497660 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03373448
Lead sponsor
Labrida AS
Responsible party
Caspar Wohlfahrt (Specialist i periodontology, Labrida AS) — Principal investigator
First posted
Dec 14, 2017
Start date
Aug 1, 2017
Primary completion
Dec 1, 2020
Completion
Dec 1, 2020
Last update
Oct 24, 2022

Study contacts

Caspar Wohlfahrt, PhD
study director · Oslo University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion